Cardiol Thereutics报告令人信服的ARCHER试验结果支持CardiolRx和CRD-38在心肌炎和心力衰竭中的进步

2025-08-06 19:29

Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.
Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass.
The ARCHER trial results provide compelling clinical proof of concept for CardiolRx™ and strongly support advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, heart failure, and myocarditis.
The ARCHER results have been submitted for presentation at an upcoming scientific meeting and will be submitted for publication.